04-06-2012: AudioCure Pharma concentrates on the clinical development of drug candidates in neurodegenerative disease indications with a high unmet medical need. The lead candidate is a small molecule compound for the treatment of acute and chronic hearing impairments via local, regenerative therapy of the damaged nerve cells in the inner ear.
Seed financing from High-Tech Gründerfonds and business angel Dr. Schumacher will enable AudioCure to develop the lead compound for the medicinal treatment of hearing impairments in the preclinical phase. The first part of solving the problem targets the ototoxic side effects of cytostatics. The second field of application addresses the hearing impairments of acoustic trauma, tinnitus and acute hearing loss, later indications target hearing loss due to advancing age.
As a consequence of increasing life expectancy, the prevalence of neurodegenerative disorders is rising significantly worldwide. This is because genetic causes are only significant 5-10% of the time, while age plays the key role in a far larger number of cases. Thus, approx. 1% of people over the age of 65 and approx. 5% of those over 85 are affected by Parkinson’s disease. Worldwide, 580 million people suffer from moderate to severe hearing impairment – with an upwards trend. Medications currently applied for these indications do not show sufficient efficacy; hearing aids and surgical intervention are inadequate and costly.
Apart from the specific causes, there are many shared mechanisms in the pathogenesis of different neurodegenerative disorders. These include, for example, inflammatory processes, damaging oxygen-based free radicals, disrupted functioning of mitochondria and programmed cell death (apoptosis). AudioCure Pharma develops substances that significantly influence these processes. Additionally, the formation of a whole series of neurotrophins (nerve growth factors) activate the natural repair mechanisms.
Professor Rommelspacher explains, “Our approach envisions placing the compound locally in the middle ear, close to the area of the disorder. We were able to demonstrate that from there it enters the inner ear and acts to reduce inflammation, and to protect and regenerate cells. The efficacy spectrum is unique. Based on our current understanding of the pathological process a therapeutic effect on the sensory and nerve cells in the inner ear is anticipated. Among these, impairments to mitochondrial function, inflammatory processes and programmed cell death are being discussed as decisive pathological processes.”
Drug Response Dx GmbH (DRDx GmbH) concluded its first round of financing with High-Tech Gründerfonds and QIAGEN. The investment will serve to develop a biomarker test kit for rheumatoid arthritis treatment guidance with so-called TNF-alpha inhibitors. The test is secured by a patent platfor ... more
InnoCyte GmbH has won three renowned investors for their cause: In a first round of financing, High-Tech Gründerfonds (HTGF), the Mittelständische Beteiligungsgesellschaft (MBG) – within the framework of the Seedfonds Baden-Württemberg – and Fraunhofer Venture have increased the capital of ... more
GeneQuine Biotherapeutics announced the completion of a seven-figure seed financing round. Investors are the German seed funds High-Tech Gründerfonds, Bonn and Innovationsstarter Fonds Hamburg. Funding will be used to perform proof-of-concept studies with the lead product – a gene therapy d ... more